Education
About Us
Working with TipRanks
Follow Us
AdAlta Ltd. (AU:1AD)
ASX:1AD
1AD Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.03
Previous CloseN/A
Volume270.05K
Average Volume (3M)574.71K
Market Cap
AU$2.68M
Enterprise ValueAU$6.86M
Total Cash (Recent Filing)AU$1.63M
Total Debt (Recent Filing)AU$1.63M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Aug 22, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,071,316,500
10 Day Avg. Volume957,709
30 Day Avg. Volume574,705
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)4.00
Price to Sales (P/S)0.00
P/FCF Ratio-1.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
AdAlta Ltd. News
PremiumCompany Announcements
AdAlta Ltd. Announces Director Departure
PremiumCompany Announcements
AdAlta Limited Announces Board Change Amid Strategic Shift
PremiumCompany Announcements
AdAlta Ltd Announces Director’s Interest Change
PremiumCompany Announcements
AdAlta Ltd. Announces Quotation of New Securities on ASX
PremiumCompany Announcements
AdAlta Ltd. Issues 2 Million New Options in Fundraising Initiative
PremiumCompany Announcements
AdAlta Completes Rights Issue, Raises $1.3 MillionPremiumCompany Announcements
AdAlta Ltd Announces Director’s Change in Securities Holdings
PremiumCompany Announcements
AdAlta Ltd. Announces Substantial Shareholding DisclosureOptions Prices
Currently, No data available
---
Ownership Overview
1.88% Insiders
―
Mutual Funds
― Other Institutional Investors
98.12% Public Companies and
Individual Investors
1AD FAQ
What was AdAlta Ltd.’s price range in the past 12 months?
AdAlta Ltd. lowest share price was AU$0.01 and its highest was AU$0.03 in the past 12 months.
What is AdAlta Ltd.’s market cap?
AdAlta Ltd.’s market cap is AU$2.68M.
When is AdAlta Ltd.’s upcoming earnings report date?
AdAlta Ltd.’s upcoming earnings report date is Aug 22, 2025 which is in 46 days.
How were AdAlta Ltd.’s earnings last quarter?
AdAlta Ltd. released its earnings results on Feb 20, 2025. The company reported -AU$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.004.
Is AdAlta Ltd. overvalued?
According to Wall Street analysts AdAlta Ltd.’s price is currently Overvalued.
Does AdAlta Ltd. pay dividends?
AdAlta Ltd. does not currently pay dividends.
What is AdAlta Ltd.’s EPS estimate?
AdAlta Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AdAlta Ltd. have?
AdAlta Ltd. has 1,071,316,500 shares outstanding.
What happened to AdAlta Ltd.’s price movement after its last earnings report?
AdAlta Ltd. reported an EPS of -AU$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of AdAlta Ltd.?
Currently, no hedge funds are holding shares in AU:1AD
AdAlta Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:1AD Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth AU$40.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-392.18%
Trailing 12-Months
Asset Growth
-55.84%
Trailing 12-Months
Company Description
AdAlta Ltd.
AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company's lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has collaborative partnerships with GE Healthcare to discover i-bodies that bind to granzyme B; and Carina Biotech Pty Ltd. to develop CAR-T cell products against various solid tumor antigens. AdAlta Limited was incorporated in 2006 and is headquartered in Bundoora, Australia.
Vectus Biosystems Limited
―
Regeneus Ltd.
―
Anatara Lifesciences Ltd
―
Bio-Gene Technology Ltd.
―
Hexima Ltd
―